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Abstract
Background: Migraine is a polygenic multifactorial disease, possessing environmental and genetic
causative factors with multiple involved genes. Mutations in various ion channel genes are
responsible for a number of neurological disorders. KCNN3 is a neuronal small conductance
calcium-activated potassium channel gene that contains two polyglutamine tracts, encoded by
polymorphic CAG repeats in the gene. This gene plays a critical role in determining the firing
pattern of neurons and acts to regulate intracellular calcium channels.
Methods: The present association study tested whether length variations in the second (more 3')
polymorphic CAG repeat in exon 1 of the KCNN3 gene, are involved in susceptibility to migraine
with and without aura (MA and MO). In total 423 DNA samples from unrelated individuals, of
which 202 consisted of migraine patients and 221 non-migraine controls, were genotyped and
analysed using a fluorescence labelled primer set on an ABI310 Genetic Analyzer. Allele frequencies
were calculated from observed genotype counts for the KCNN3 polymorphism. Analysis was
performed using standard contingency table analysis, incorporating the chi-squared test of
independence and CLUMP analysis.
Results: Overall, there was no convincing evidence that KCNN3 CAG lengths differ between
Caucasian migraineurs and controls, with no significant difference in the allelic length distribution
of CAG repeats between the population groups (P = 0.090). Also the MA and MO subtypes did not
differ significantly between control allelic distributions (P > 0.05). The prevalence of the long CAG
repeat (>19 repeats) did not reach statistical significance in migraineurs (P = 0.15), nor was there
a significant difference between the MA and MO subgroups observed compared to controls (P =
0.46 and P = 0.09, respectively), or between MA vs MO (P = 0.40).
Conclusion: This association study provides no evidence that length variations of the second
polyglutamine array in the N-terminus of the KCNN3 channel exert an effect in the pathogenesis of
migraine.
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Background
Migraine is a common, debilitating neurovascular disease
characterised by severe recurrent headache, nausea and
vomiting, photophobia and phonophobia [1]. It is clini-
cally diagnosed based on criteria specified by the Interna-
tional Headache Society (IHS), defining two major classes
of migraine: migraine with aura (MA) and migraine with-
out aura (MO). MA sufferers experience neurovascular
disturbances that precede the headache phase of an attack.
Although migraine is partly influenced by environmental
determinants, there is a significant genetic component,
with disease heritability estimated to be up to 60% [2]
and mode of transmission multifactorial. The disorder is
common with a large Dutch study reporting lifetime prev-
alence estimates of 33% in women and 13.3% in men [3].
Allelic candidate gene, studies provide the most suitable
method for locating genes of small effect contributing to
complex genetic disorders, such as migraine [4,5]. In par-
ticular, association studies are most powerful when a
plausible candidate gene and a sequence variant with
potential functional relevance is examined [6].
Mutations in various ion channel genes are responsible
for neuromuscular and other neurological disorders.
Inherited ion channel mutations or "channelopathies" are
increasingly found to be the cause of various neurological
disorders in humans (see review [7]). In familial hemiple-
gic migraine (FHM), a rare subtype of migraine with aura,
mutations in the CACNA1A gene (localised at C19p13)
have been found (FHM1) [8]. This gene codes for the
alpha1A subunit of the neuronal voltage-dependent P/Q-
type calcium channel. Recently a second gene, ATP1A2
(FHM2) (localised at C1q23), was implicated in some
FHM families [9]. The ATP1A2 ion channel gene, codes
for the alpha2 subunit of the Na+, K+ ion ATPase pump.
These findings of mutations in these genes have focused
attention on central nervous system ionic channels and
helped to better understand FHM pathophysiology [10],
where the best genetic evidence providing molecular
insight into migraine still comes from the mutations
detected in the rare form of migraine with aura; FHM [11].
The CACNA1A and ATP1A2 genes have both previously
been tested in the common forms of migraine, but no new
mutations or the FHM mutations were detected in these
MA/MO affected samples [12-14]. Since FHM2-ATP1A2 is
partly a potassium channel gene and is localised nearby to
the potassium channel KCNN3, it may be interesting to
investigate this gene in the common forms of migraine. In
general, potassium (K+) channels set the resting mem-
brane potential and regulate the action potential, whereby
they control neuronal excitability. The small conductance
(SK) calcium (Ca2+) activated K+ channels are responsible
for the "after-hyperpolarization" of neurons, which fol-
lows a train of action potentials, being activated by the
increase in neuronal Ca2+  [15]. The KCNN3  gene
(C1q21.3) (a neuronal small conductance calcium-acti-
vated potassium channel, localised close to FHM2-
ATP1A2;C1q23) encodes a protein of 731 amino acids
containing two adjacent polyglutamine arrays (encoded
by CAG repeats) in its N-terminal domain separated by 25
amino acids [16]. The first CAG repeat, coding for a poly-
glutamine stretch in exon 1 at nucleotide 88, also contains
a CAA sequence anomaly after 7 repeats of CAG. However
this CAG repeat region is not suitable for association stud-
ies as it is only slightly polymorphic having usually 12
CAG repeats [15,16]. The second, C-terminal, poly-
glutamine array, located 111 nucleotides downstream
from the initial CAG repeat of the first polyglutamine
stretch in exon 1, is highly polymorphic in Caucasian
populations with a modal allele length of 19 and a repeat
range of 10 to 28 glutamine – CAG repeats [see [15] and
[16]]. Small conductance calcium-activated potassium
channels (such as KCNN3) play a critical role in determin-
ing the firing pattern of neurons via the generation of slow
after-polarization and the regulation of intracellular cal-
cium channels [17].
KCNN3, localized at C1q21.3 [15], is positioned close to
familial hemiplegic migraine (FHM) type 2, C1q23
[9,18], which is a severe autosomal dominant type of MA
[1]. In 1999, Austin et al [19] suggested a mechanistic
analogy for the KCNN3 polymorphism may be the small
polyglutamine number variations in the calcium channel
α1a subunit, encoded by CAG expansions in CACNA1A (a
calcium channel implicated in FHM1) [8] which are
thought to cause Spinocerebellar ataxia type 6 (SCA6)
[20] by loss of channel function mechanism [21].
Polymorphic CAG repeats in the KCNN3 channels affect
the regulation of intracellular calcium channels [17].
Since calcium channels regulate numerous processes crit-
ical to neuronal function including secretion of neuro-
transmitters [22], abnormal alterations in calcium
channels can cause alterations in the release of neuro-
transmitters such as serotonin, norepinephrine, and
dopamine, which all have been shown to be involved in
migraine disease [23-25].
Given that FHM2 maps to C1q23 and KCNN3 localizes
nearby at C1q21.3, it may be important to examine the
prevalence of the second (highly polymorphic) KCNN3
CAG polymorphism in populations affected and unaf-
fected with migraine. In the current study, we investigated
the possibility of an association between migraine (MA
and MO affected) and the second (more 3') CAG repeat
polymorphism length variation within the KCNN3 gene,
using a case-control study of unrelated Australian Cauca-
sian migraine patients and ethnically matched controls.BMC Medical Genetics 2005, 6:32 http://www.biomedcentral.com/1471-2350/6/32
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Methods
Subjects
This study was approved by the Griffith University Ethics
Committee and all subjects who participated gave
informed consent. The subjects chosen were of Caucasian
origin and were categorised based on the diagnostic crite-
ria specified by the International Headache Society (IHS)
[1]. Migraine individuals were diagnosed as having
migraine with aura (MA) and migraine without aura
(MO) from questionnaires and interviews conducted by
an experienced clinical neurologist (JM).
In total, 423 DNA samples from unrelated individuals
were analysed, of which 202 consisted of migraine
patients and 221 non-migraine controls. Of the affected
group, 90% of patients had a known family history of
migraine, or at least one affected first degree relative. Clin-
ically, the affected group had an average age of approxi-
mately 18 yrs disease onset, while average duration of
migraine was 20 hours and frequencies of approximately
30 attacks per year. The unaffected control group was
recruited from the same geographical location (East Coast
of Australia) as the affected group and was matched to the
case samples for variables of age (± 5 years), gender and
ethnicity (Caucasian). This reduces the possibility of spu-
rious results due to underlying population stratification.
Individuals that reported being affected with known
migraine comorbid conditions such as mental illness (eg.
depression) and cardiovascular disease (eg. stroke) were
excluded from the test groups.
Genotyping
Genomic DNA was isolated from whole blood by a stand-
ard salting out procedure [26,27]. DNA fragments con-
taining the second KCNN3  CAG polymorphism were
amplified by PCR using the oligonucleotides published by
Austin et al, 1999 [19]. The sense primer sequence was 5'-
CAG CAG CCC CTG GGA CCC TCG C-3', and the anti-
sense 5'-GGA GTT GGG CGA GCT GAG ACA G-3'. PCR
constituents consisted of the following; 1X buffer J (Mas-
ter Amp™, EPICENTRE® Technologies), 0.2 µM each of for-
ward and reverse primers, 1 unit of Taq polymerase and
40 ng of genomic DNA, mixed with H20 in a final volume
of 10 ul. Thermal cycler parameters consisted of 1 cycle at
95°C for 4 min, for initial denaturation, followed by 35
cycles of denaturation for 1 min at 94°C, primer anneal-
ing at 55°C for 1 min and primer extension at 72°C for 30
sec. Final PCR extension consisted of 72°C for 2 min [19].
The DNA samples were genotyped using an ABI PRISM™
310 Genetic Analyzer and a FAM fluorescent dye labelled
forward primer (utilized in the PCR reaction). Raw data
was imported into the ABI PRISM™ Genotyper v2.0 DNA
Fragment Analysis Software, whereby genotypes were
individually called. Independent quality control analysis,
performed by a laboratory technician, for the CAG variant
consisted of PCR and genotyping of a random selection of
50 cases and controls to test for any differences between
initial genotype data.
Statistical analysis
Allele frequencies were calculated from observed geno-
type counts for the KCNN3 polymorphism. The frequen-
cies for the KCNN3 gene variant were initially assessed for
association with migraine using standard contingency
table analysis, incorporating the chi-squared test of inde-
pendence. CLUMP analysis [28], useful for association
testing when markers produce sparse contingency tables,
was applied to test differences in the allelic distribution
between the groups of migraine and controls patients. A
two-tailed type I error rate of 5% was chosen for the anal-
yses. Data were analysed by methods described previ-
ously, based on the mode of distribution of alleles, with a
modal repeat length of 19 CAG repeats [16] and the
hypothesis of an association between migraine and larger
repeats (>19) analysed by chi-square analysis. Allele sizes
were divided into long and short groups with respect to
being greater than 19 repeats or equal to and less than 19
CAG repeats in length.
Results
The distribution of allele frequencies for migraine patients
compared to controls are displayed in Figure 1, with the
distributions of allele frequencies for MA patients, MO
patients and controls displayed in Figure 2. Both figures
show CAG repeat number along the X-axis versus fre-
quency of distributions (%) displayed along the Y-axis.
The repeat range is 12 to 24 repeats in migraine patients,
not including the repeat lengths of 22 and 23. For the con-
trols the range is 12 to 26 repeats, except for the 24 CAG
repeat size. This displays the highly polymorphic nature
of the second CAG expansion within the KCNN3 gene. No
significant differences in allelic distributions were
observed between the migraine and control groups for
standard chi-square analysis (P  = 0.090) (Figure 1).
Clump analysis, for normal chi-square, also showed no
significant difference reported (T1 = 20.111, P = 0.090).
However for chi-square clumped 2×2 table analysis
(obtained by clumping the columns of the original table
to maximise the chi-squared value) [28], between
migraine and controls, slightly significant differences were
detected within the test data (T4 = 13.001, P = 0.037) (Fig-
ure 1). This indicates that there maybe a slight significant
difference between the case-control populations with
regards to clumped 2×2 table KCNN3 allele distributions.
The T3 statistic was also positive for CLUMP analysis (P =
0.025) (Figure 1), although, Sham and Curtis [28] recom-
mends that either normal chi-squared (T1) or chi-squared
for "clumped" 2×2 table (T4) analysis should be used. The
other two statistics (T2, T3) may lack power to detectBMC Medical Genetics 2005, 6:32 http://www.biomedcentral.com/1471-2350/6/32
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association in data sets studied, whereas T1 and T4 per-
form similarly well [28].
When dividing migraine affected samples into the sub-
types MA and MO, distribution of alleles did not differ sig-
nificantly between MA patients and controls (P > 0.05) or
MO patients and controls (P > 0.05) (Figure 2). Analysis
was also performed by distributing the alleles into ≤19
(short) and >19 repeats (long) (Table I), described as per
Chandy et al, 1998 [16]. The hypothesis of the presence of
very long CAG repeats might be expected for a disorder
relating to trinucleotide repeat expansion [16]; this was
tested by chi-square analysis. Migraine probands showed
no significant difference in allelic length distribution of
the CAG repeats compared with controls (P  = 0.15).
Though the number of long CAG repeats (>19 repeats)
was higher in the migraine group (92 compared to 83 for
controls, Table 1) and the incidence of the CAG short
repeat (<19 repeats) was higher in the control (359) group
than in the migraine (312) group. Similarly, the allele fre-
quency distributions for the migraine subgroups, MA and
MO compared to controls did not approach significance
(P = 0.46 and P = 0.09, respectively), or between MA vs
MO (P = 0.40) (Table I).
Discussion
Polyglutamine disorders are due to CAG repeat expan-
sions that cause a toxic gain of function of mutant
expanded proteins, in which protein misfolding, interfer-
ence with DNA transcription and RNA processing, activa-
tion of apoptosis and dysfunction of cytoplasmic
elements have all been invoked in the toxic process. [29].
These CAG expansions have been involved in a number of
neurological diseases, including Huntington's disease
(HD), Dentatorubralpallidoluysian atrophy (DRPLA),
Kennedy's disease and Spinocerebellar ataxia (SCA) 1–3,
6–7, 12 and 17 [29].
Migraine is a polygenic multifactorial disease influenced
by genetic and lifestyle characteristics. At present the
mode(s) of inheritance is unclear and the type and
number of migraine genes involved in the disease is not
known. Since both FHM and familial typical migraine
(FTM) display some clinical overlap [1], it is thought that
Distribution of allele frequencies by CAG repeat number for the second CAG polymorphism of the KCNN3 gene observed in  migraine and control groups Figure 1
Distribution of allele frequencies by CAG repeat number for the second CAG polymorphism of the KCNN3 gene observed in 
migraine and control groups.
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the more prevalent FTM may also be a channelopathy
[30]. The CACNA1A gene, involved with FHM1 [8] con-
trols a number of fundamental neuronal processes includ-
ing mediation and release of neurotransmitters such as
serotonin [31]. The KCNN3 gene acts to regulate the firing
pattern of neurons via the generation of slow after-polari-
zation and the regulation of intracellular calcium chan-
nels [17]. Patients with migraine have autonomic nervous
system dysfunction and altered levels of neurotransmit-
ters. Therefore, decreases in activity and regulation of
intracellular calcium channels, that may be caused by
CAG repeat expansions in the KCNN3 gene, would result
in decreased levels of neurotransmitters (such as serot-
onin) and autonomic nervous system dysfunction. These
states appear to be analogous to those found during
migraine headache in that decreases in plasma levels of
serotonin would essentially act to constrict the arterioles,
therefore causing dilation of the larger arteries, possibly
causing pain [32,33].
Wittekindt et al, 1998 [15] reported that the KCNN3 gene
is a good candidate for schizophrenia and bipolar disor-
der (BD), as well as for other neurological disorders. This
includes migraine, a painful neurological disease that
affects 33% of women and 13.3% of men [3].
However, even though there was a slight indication of sig-
nificance in one analysis (clump T4 statistic) [28], overall
the results of this study proved that there was no statisti-
cally significant association between allelic frequencies of
migraine and non-migraine patients. Also no significant
difference in allelic frequencies was observed in the
migraine subtypes, MA and MO when compared to the
control population. There have been many contradicting
studies that have shown a significant over-representation
or non-significant representation of long CAG repeats in
the KCNN3 gene in patients with schizophrenia and bipo-
lar disease compared to population controls [see [34]]. In
a meta-analysis of association studies for schizophrenia
and bipolar disorder with the CAG-repeat length in
KCNN3, the results demonstrated that the risks for both
of these disorders were largely, if not entirely, independ-
ent of the CAG-repeat in the KCNN3 gene [34]. This study
examined CAG repeat lengths (the second, C-terminal,
polyglutamine array in exon 1 of KCNN3) in migraine
patients and also found no significant evidence to suggest
long CAG repeats (>19) are over-represented in patients
with migraine compared to controls, even though there
was a higher incidence reported for long CAG repeat (>19
repeats) in the migraine group compared to the controls
(Table I), it did not reach statistical significance (P < 0.05).
However, a recent study by Mossner et al, 2005 [35],
reported an association between the second highly poly-
morphic polyglutamine stretch and migraine. In this
study the authors found allele 15 to be associated with
migraine (P  = 0.027; total migraine) [35]. Allele 15 is
extremely rare with a 1.6% frequency in MA, 1.5% in MO
and a 0.2% control frequency found in Mossner et al's
study [35]. In our investigation of the second KCNN3 –
CAG repeat we found a frequency in allele 15 of 0.9% in
MA (only 2 out of 222 alleles), 1.65% in MO (3 out of 182
alleles) and 0.9% in controls (4 out of 442 alleles) (see
distribution of alleles, Figures 1 and 2). From the two
studies it can be seen that this allele is too rare to make
any assumptions of whether it is migraine related. A pop-
ulation base far greater in number is needed in order to
obtain meaningful data from allele 15. Also, the fact that
this study utilised samples that were all carefully diag-
nosed following IHS guidelines [1], including all samples
from the migraine unaffected-control population and
Mossner et al, 2005 [35] did not, leaves their positive
results questionable. Mossner et al had made a migraine-
unaffected assumption with more than half their controls
(119/232 samples). These individuals that were utilised as
controls, were an undiagnosed, anonymous blood donor
group [35], that were not directly interviewed or diag-
nosed according to the International Headache Society
guidelines [1]. This could have a tremendous impact on
the outcomes of their study, due to the rarity of allele 15
in the second CAG repeat of exon1 in KCNN3.
The present association study was conducted in carefully
diagnosed (according to IHS guidelines [1]), age, sex and
ethnicity matched case-control populations. However the
results provided no evidence that KCNN3 gene confers
susceptibility to the subtypes of migraine (MA and MO),
or common migraine.
Conclusion
We conclude that our data does not confer with Mossner
et al, 2005 [35], providing no evidence that a variation at
Table 1: Long (>19 repeats) and short (≤19 repeats) alleles: CAG 
repeat number in KCNN3; analysis performed utilising the 
comparison of long and short allele repeat numbers between 
migraine and control populations.
Allele Size
Group Short (≤19rpts) Long (>19rpts)
MA 175 47
MO 137 45
Migraine (Total) 312 92
Control 359 83
* Analysis of long and short alleles: no significant differences were 
obtained between migraine vs control groups (P = 0.15), MA vs 
controls (P = 0.46), MO vs controls (P = 0.09), or between MA vs MO 
(P = 0.40)BMC Medical Genetics 2005, 6:32 http://www.biomedcentral.com/1471-2350/6/32
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the polymorphic, second CAG repeat locus, in the KCNN3
gene, influences susceptibility to migraine, or to the
migraine subtypes, MA and MO.
List of abbreviations
KCNN3  neuronal small conductance calcium-activated
potassium channel, subfamily N, member 3, MA migraine
with aura, MO migraine without aura.
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